The European Commission has authorized GSK’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 77.16 pounds, according to the company.
Sold under brand name Apretude, it is currently approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
Today Breeze.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by . The content will be deleted within 24 hours.